Covance, Inc. today announced that Douglas M. Fast, Ph.D. has joined the company as Scientific Director Bioanalytical Services. With more than 16 years of drug development industry experience, including bioanalytical assay development, validation and sample assays for non-clinical and clinical studies, Dr. Fast will lead the North American staff scientist and principal investigator teams for Covance small molecule bioanalytical services.
Dr. Fast joins Covance from Pfizer Global Research and Development where he served as director of regulated bioanalytical research in Pharmacokinetics, Dynamics and Metabolism. As a member of the Pfizer leadership team, he provided bioanalytical support for nonclinical and first-in-human studies. Dr. Fast also led a global process harmonization team for GLP assay work across sites in the US, UK, and Japan.
“Doug’s proven experience in drug development, bioanalysis, and knowledge of regulatory guidance will be an asset to the Covance team and our client partners,” said Steven Michael, Vice President and Chief Scientific Officer, Global Bioanalytical Services, Covance.
In addition to his technical expertise and over 25 years of mass spectrometry experience, Dr. Fast is an expert on bioanalysis regulatory guidelines. He was a key contributor to the creation and publication of the Crystal City Guidelines for Incurred Sample Reanalysis (ISR). Dr. Fast currently serves as chair of the Regulated Bioanalysis Workshop of the 2010 Applied Pharmaceutical Analysis Conference.
Dr. Fast received a doctorate in analytical chemistry from Purdue University. He is a member of the American Society of Mass Spectrometry, the American Chemical Society, and the American Association of Pharmaceutical Scientists and has been published in various scientific publications including Journal of Pharmaceutical and Biomedical Analysis, Journal of Mass Spectrometry, and Journal of Chromatography.
With a six-site, global network of flexible bioanalytical resources, the Covance bioanalytical services team develops and validates more than 550 methods every year to support drug development from discovery through Phase IV.
Covance (covance.com), with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company’s business are based largely on management’s expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company’s ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company’s filings with the Securities and Exchange Commission.